The Patent Finder
US

Antibody to Genetic Products Differentially Expressed in Tumors and the Use Thereof

US 9,775,785 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended Nov 21, 2023 · High confidence

Filed Apr 1, 2015 as application 14/676,254 · Granted Oct 3, 2017
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
20 years from filing
Term ended Nov 21, 2023
2005 2026
Clock starts
May 18, 2005
Term ended
Nov 21, 2023
Granted
Oct 3, 2017
base term after the term ends fee events Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 7,527,933.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts May 18, 2005, when application PCT/EP2005/005410, the earliest non-provisional in its chain, was filed (this one was filed Apr 1, 2015)May 18, 2025High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,527,933)capped to Nov 21, 2023High confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderNov 21, 2023High confidence

This family

US 9,044,382In force
Aug 2027
Aug 2027
US 9,775,785this patent
Nov 2023
Nov 2023
Application 15/448,831Abandoned
not computed
not computed
Application 17/079,326Abandoned
not computed
not computed
4 of 5 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Aug 23, 2017
Reel 43367, frame 673
Tureci, Ozlem; Sahin, Ugur; Koslowski, MichaelGanymed Pharmaceuticals AGAssignment of Assignor's Interest
Aug 23, 2017
Reel 43367, frame 809
Tureci, Ozlem; Sahin, Ugur; Koslowski, Michael; Fritz, Stefan; Geppert, Harald-gerhardGanymed Pharmaceuticals AGAssignment of Assignor's Interest
Mar 5, 2020
Reel 52032, frame 41
Ganymed Pharmaceuticals GmbHAstellas Pharma Inc.Assignment of Assignor's Interest
Mar 5, 2020
Reel 52114, frame 186
Ganymed Pharmaceuticals AGGanymed Pharmaceuticals GmbHChange of Name

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited